Tag: Alzheimer’s
Choroid Plexus Volume Up With Advanced Cognitive Impairment
Larger volume associated with severity of cognitive impairment across Alzheimer disease spectrum
One in Three Alzheimer, Dementia Cases Tied to Modifiable Risk Factors
Risk factors differ based on sex and race and ethnicity
FDA OKs Marketing of New Test to Help Diagnose Alzheimer Disease
Lumipulse G β-Amyloid Ratio (1-42/1-40) test is first in vitro diagnostic test for early detection of amyloid plaques associated with Alzheimer disease
Interventions for Alzheimer Disease Improve Cognition in Men, Women
Individualized multidomain interventions equally effective for improving cognition in women, men
Race May Impact Accuracy of Models Predicting Brain Amyloidosis
Models using plasma Aβ42/Aβ40 to predict probability of CSF Aβ42/Aβ40 positivity not affected by race
DMARDs Not Linked to Alzheimer Risk for Seniors With RA
No reduction in ADRD risk seen for treatment with tofacitinib, tocilizumab, TNF inhibitors versus abatacept
Alzheimer Disease, Related Dementia Diagnoses Up in Medicare Decedents
Percentage of older U.S. decedents with a diagnosis of Alzheimer disease and related dementias increased significantly from 2004 to 2017
Excess Mortality Seen for Seniors With Alzheimer Disease, Dementia in COVID-19
Enrollees with ADRD had increased adjusted mortality, especially for Asian, Black, Hispanic populations with ADRD
Neuroimaging Measures Linked to Stages of Memory Impairment
Presence of Alzheimer disease pathology related to Stages of Objective Memory Impairment in cognitively unimpaired older adults
AAN Issues Review of Evidence for Aducanumab in Alzheimer Disease
Class I study shows single doses of aducanumab safe, well tolerated; class II studies show reduced amyloid deposition on brain PET at one year
